DraftKings Legal Chief Takes Helm at Top Hospital: A New Governance Playbook

DENVER, CO – July 29, 2026 – National Jewish Health, the nation’s leading respiratory hospital, has named R. Stanton Dodge as the new chair of its Board of Directors. The appointment places a seasoned corporate strategist and legal heavyweight, currently the chief legal officer of DraftKings, at the helm of a world-renowned medical institution. While Dodge has served on the hospital's board for 16 years, his ascent to the chair signals a significant moment—not just for the Denver-based facility, but as a reflection of a broader evolution in how healthcare institutions are seeking to navigate an increasingly complex future.

A New Playbook for Healthcare Governance

Dodge’s resume reads like a blueprint for navigating high-stakes, regulated industries. At DraftKings, he manages the company's legal, government affairs, and corporate communications, a role that has seen him steer the sports-tech giant through its public listing and explosive growth across a patchwork of state laws. Before that, he spent over two decades at DISH Network, rising to executive vice president and general counsel of the Fortune 200 telecommunications firm. His tenure there included landmark legislative victories, such as his work on the Satellite Television Extension and Localism Act (STELA), which fundamentally changed the competitive landscape for satellite providers.

This background in corporate law, regulatory strategy, and market disruption is precisely what many see as a critical asset for modern healthcare. The industry is no longer just about medicine; it's about technology, data, intricate policy, and fierce competition. Dodge’s track record demonstrates an acute ability to adapt and innovate under pressure. Colleagues from his time at DraftKings recall his “don’t panic” philosophy during the early days of the COVID-19 pandemic, where he helped pivot the company toward new free-to-play games based on reality shows and political debates to maintain customer engagement when live sports vanished. This kind of agile, strategic problem-solving is a valuable commodity in any sector, but especially in healthcare, which is grappling with its own seismic shifts.

In the official announcement, National Jewish Health President and CEO Dr. Michael Salem lauded Dodge's unique qualifications. "Stanton's exceptional leadership, legal expertise and longstanding commitment to National Jewish Health make him uniquely qualified to lead our Board of Directors," said Dr. Salem. "His strategic vision, dedication to our mission and deep understanding of our organization will help guide National Jewish Health as we continue advancing patient care, research and education."

Continuity and a Calculated Evolution

While Dodge brings a distinct corporate perspective, his appointment is also a masterclass in leadership continuity. Having served on the board for 16 years, he possesses a deep institutional knowledge that an outside appointee would lack. He is not a disruptive force entering a stable system, but rather a known entity being tasked with accelerating its evolution. He succeeds Evan Zucker, who has led the board since July 2023 and will continue to serve as a member of the board and its executive committee, ensuring a seamless transition.

Zucker's tenure, though brief, was pivotal. He successfully guided the institution through its 125th anniversary in 2025, a milestone that celebrated its rich history since its founding in 1899 as a nonprofit hospital for tuberculosis patients. More strategically, Zucker oversaw the development of a “significant 10-year planning process” designed to position the hospital for sustained growth and innovation. This long-term roadmap, which Dodge now inherits, provides a clear strategic framework for the next decade.

Dr. Salem extended his gratitude to the outgoing chair, noting Zucker’s role in "helping guide National Jewish Health through its 125th anniversary celebration in 2025, and leading the institution through a significant 10-year planning process to position National Jewish Health for continued growth and innovation." The groundwork has been laid, and Dodge is now the architect tasked with building upon it.

The Boardroom Blueprint: Why Corporate DNA is Reshaping Medicine

Dodge's appointment is emblematic of a wider trend in healthcare governance: the deliberate recruitment of non-medical professionals to lead hospital boards. As healthcare organizations function more like complex, multi-billion-dollar enterprises, their boards are seeking the business acumen, financial discipline, and strategic foresight that corporate veterans provide. The modern hospital CEO must contend with supply chain logistics, cybersecurity threats, digital transformation, and intricate reimbursement models—challenges familiar to any C-suite executive.

Leaders with backgrounds in law and regulated industries are particularly sought after. Their expertise in risk management, compliance, and government relations is invaluable in an industry defined by its dense legal framework. The ability to anticipate policy shifts, influence legislation, and negotiate strategic partnerships can be as critical to a hospital's health as its clinical outcomes. This diversification of board leadership injects a new form of intellectual capital into these mission-driven organizations, balancing medical expertise with operational and strategic rigor.

Charting the Next Decade for a Medical Pioneer

As Dodge takes the chair, he will be responsible for executing the ambitious 10-year plan established under his predecessor. For National Jewish Health—the only facility in the world dedicated exclusively to the research and treatment of respiratory, cardiac, and immune disorders in both children and adults—this plan will undoubtedly involve pushing the frontiers of medical science and patient care. The institution’s future growth will likely hinge on expanding its world-class research programs, investing in cutting-edge technologies like telehealth, and forging new collaborations with academic and biotech partners.

Here, Dodge's corporate experience becomes directly applicable. His leadership in taking DraftKings public and navigating its expansion into new markets provides a playbook for securing major funding, whether through capital campaigns or sophisticated financial partnerships. His extensive civic engagement, which includes serving on the boards of EchoStar Corporation, the University of Vermont, and the Western Stock Show Association, demonstrates a deep-seated commitment to institutional stewardship. This blend of aggressive corporate strategy and dedicated community service positions him to champion National Jewish Health's dual identity as both a pioneering research institution and a vital nonprofit community asset. His leadership tenure will be a fascinating case study in how the DNA of corporate America can be harnessed to advance the mission of a medical leader.